Navigation Links
Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
Date:4/14/2011

WALTHAM, Mass., April 14, 2011 /PRNewswire/ -- Proteon Therapeutics, Inc. has initiated enrollment in a Phase 2 clinical study of its lead product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgery for arteriovenous fistula (AVF) creation in preparation for hemodialysis. This study follows successful completion of a 66-patient, double-blind, placebo-controlled Phase 1/2 study of PRT-201 in AVF patients that completed enrollment in July 2010.

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant medical challenges associated with vascular access in CKD patients, and we are very excited about the potential for PRT-201 to dramatically improve care for dialysis patients," said Timothy P. Noyes, President and CEO of Proteon.  

The results of this Phase 2 study will be provided to Novartis under an agreement entered into in 2009, whereby Novartis was granted an exclusive option to acquire Proteon following the completion of a Phase 2 clinical study of PRT-201. Including the initial acquisition payment plus potential regulatory milestone payments, the acquisition deal with Novartis could exceed $550 million.

About PRT-201

PRT-201 is an investigational recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) and arteriovenous graft (AVG) outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown in certain preclinical settings to reduce neointimal hyperplasia formation, and to cause dilation of segments of arteries and veins following topical intraoperative application. These effects may decrease the number of interventions necessary to maintain AVF and AVG patency. Improved patency may lead to fewer corrective surgical procedures, fewer hospitalizations, lower costs and less suffering for dialysis patients. The development program to investigate PRT-201 for
'/>"/>

SOURCE Proteon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
3. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
4. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
7. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
8. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
9. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
10. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
11. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... WASHINGTON , Jan. 14, 2014  3D Communications, a leading provider ... scientific, regulatory, business, and media events in the United ... its former associate Virginia Cox , JD, is returning to ... Virginia Cox re-joins 3D after more than two years ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense ... today reported financial and operational results for the third ... For the third quarter of 2009, PharmAthene recognized revenues ... same period of 2008. For the nine months ended ...
... ... on commercializing new patent portfolio into products and services , ... Laguna Niguel, CA (PRWEB) November 13, 2009 -- Applied Technology ... directors following the 2010 shareholders annual election of directors. , , ,Jay A. Shears ...
... Engineering and Applied Science at Northwestern University have developed, ... in atomic force microscopy (AFM), which images, measures, and ... researchers made a much more durable probe than the ... in AFM to gather information from a material, but ...
Cached Biology Technology:PharmAthene Reports Third Quarter 2009 Financial and Operational Results 2PharmAthene Reports Third Quarter 2009 Financial and Operational Results 3PharmAthene Reports Third Quarter 2009 Financial and Operational Results 4PharmAthene Reports Third Quarter 2009 Financial and Operational Results 5PharmAthene Reports Third Quarter 2009 Financial and Operational Results 6PharmAthene Reports Third Quarter 2009 Financial and Operational Results 7PharmAthene Reports Third Quarter 2009 Financial and Operational Results 8Applied Technology Holdings, Inc. Announces Board of Directors 2New nanocrystalline diamond probes overcome wear 2
(Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
(Date:4/22/2014)... the fist-like club of a mantis shrimp, a team ... collaboration with University of Southern California and Purdue University, ... is more impact resistant and tougher than the standard ... club of this tiny crustacean, the more we realize ... every day," said David Kisailus, a Kavli Fellow of ...
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2011.   Revenue for the second quarter of ... million in the same quarter last year. The net loss for ... share. These results compared to a net loss of $148,000, or ...
... Clearbridge Accelerator announced today that it has received an ... in the Silicon Valley. Mr Draper, who is the ... (DFJ), is well known for making early-stage investments in ... Accelerator is a technology incubator that focuses on commercialising ...
... , BLOOMINGTON, Ind. -- A visiting researcher from Sweden in ... has led an international team in culturing, characterizing and formally ... been identified through DNA sequencing from environmental samples. ... Archaeorhizomyces , previously known as Soil Clone Group 1 (SCG1), ...
Cached Biology News:Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6Visiting researcher at IU leads international team in formal identification of new fungi class 2Visiting researcher at IU leads international team in formal identification of new fungi class 3
... George Paxinos Affiliation: School of Psychology, The ... Watson Affiliation: Curtin University of Technology, Perth, Australia ... atlas of the rat brain. It is ... mm) revison and extension of the compact 3rd ...
... series of vacuum concentrators/centrifugal evaporators offers a ... to rapid and safe concentration of heat-labile ... with oil-free or high vacuum pumps, a ... selection of rotors (eliminating sample loss by ...
... Thermal Cycler is Thermo Electron's most advanced ... with easy to use sophisticated onboard software ... programming. Designed to offer performance, accuracy and ... a number of customer driven features built ...
Carrier Serum...
Biology Products: